Table 1 Patients' characteristics of 341 patients treated with EGFR-TKIs
Characteristics | No. of patients | % patients |
|---|---|---|
Total | 341 | 100 |
Age (years) | Â | Â |
Mean (± SEM) | 65.2(± 0.6) |  |
< 60 | 102 | 29.9 |
≥ 60 | 239 | 70.1 |
Sex | Â | Â |
Female | 167 | 49.0 |
Male | 174 | 51.0 |
Histologic type | Â | Â |
Adenocarcinoma | 296 | 86.8 |
Squamous cell carcinoma | 34 | 10.0 |
Others | 11 | 3.2 |
Smoking history | Â | Â |
Current | 60 | 17.6 |
Former | 110 | 32.3 |
Never | 171 | 50.1 |
Disease stage | Â | Â |
IV | 206 | 60.4 |
IIIB | 54 | 15.8 |
I-IIIA | 18 | 5.3 |
Recurrence after surgery | 63 | 18.5 |
Performance status | Â | Â |
≥ 2 | 141 | 41.3 |
0-1 | 200 | 58.7 |
No. of prior chemotherapy regimens | Â | Â |
≥ 2 | 118 | 34.6 |
0-1 | 223 | 65.4 |
Prior thoracic radiotherapy | Â | Â |
Yes | 47 | 13.8 |
No | 294 | 86.2 |
Preexisting pulmonary fibrosis | Â | Â |
Yes | 48 | 14.1 |
No | 293 | 85.9 |
Preexisting pulmonary emphysema | Â | Â |
Yes | 82 | 24.0 |
No | 259 | 76.0 |
EGFR mutation status | Â | Â |
Wild type | 57 | 16.7 |
Mutant | 91 | 26.4 |
Not evaluated | 193 | 56.9 |
Types of EGFR-TKI | Â | Â |
Gefitinib | 302 | 88.6 |
Erlotinib | 39 | 11.4 |